Global pharmaceutical company Sanofi has announced a partnership with US establishments to work on a vaccine for the novel coronavirus called COVID-19. They will work based on its preceding research on SARS.
Sanofi Pasteur, the global unit of Sanofi, will influence previous development work for a SARS vaccine which may unlock a fast path forward for emerging a COVID-19 vaccine. Sanofi will cooperate with the Biomedical Advanced Research and Development Authority.
The French pharmaceutical company will develop a vaccine applicant to counter the new coronavirus using its licensed recombinant DNA platform. This DNA platform enables scientists to produce an exact heritable match to proteins found on the external of the virus.
The researchers will produce large amounts of the coronavirus antigen that will stimulate a person’s immune system to protect them against the virus.
The Sanofi’s platform will have the potential to manufacture large amounts of the vaccine candidates. According to the company’s statement similar initiatives have been undertaken by big pharma businesses that have tied up with the US for investigation on an antidote for the virus including Regeneron and Johnson & Johnson.
In China’s latest report, the death toll after the virus has surpassed 2000 in China alone with over 11000 serious cases. Over 74000 cases of the virus have been reported so far as per media reports.
